Medpace Holdings, Inc. (MEDP)

Market Cap	12.88B +16.7%
Revenue (ttm)	2.53B +20.0%
Net Income	451.12M +11.6%
EPS	15.28 +21.0%
Shares Out	28.38M
PE Ratio	29.70
Forward PE	26.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	394,067
Open	440.93
Previous Close	446.44
Day's Range	440.93 - 454.71
52-Week Range	250.05 - 628.92
Beta	1.40
Analysts	Hold
Price Target	496.09 (+9.33%)
Earnings Date	Feb 9, 2026

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data man...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 6,200
• Stock Exchange: NASDAQ
• Ticker Symbol: MEDP
• Website: https://www.medpace.com

Financial Performance

In 2025, Medpace Holdings's revenue was $2.53 billion, an increase of 19.97% compared to the previous year's $2.11 billion. Earnings were $451.12 million, an increase of 11.57%.

Analyst Summary

According to 12 analysts, the average rating for MEDP stock is "Hold." The 12-month stock price target is $496.09, which is an increase of 9.33% from the latest price.

Price Target

$496.09

(9.33% upside)

Analyst Consensus: Hold